申请人:Bristol-Myers Squibb Company
公开号:US10954225B2
公开(公告)日:2021-03-23
The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMDA) receptor and thereby making them useful for the treatment of various disorders of the central nervous system.
本公开提供了式(I)化合物及其药学上可接受的盐类。式(I)化合物是 NR2B N-甲基-D-天冬氨酸(NMDA)受体的配体,因此可用于治疗中枢神经系统的各种疾病。